4-oxo-3-piperidinecarboxylate hydrochloride | 856213-34-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 4-oxo-3-piperidinecarboxylate hydrochloride
• 英文别名: 4-oxopiperidine-3-carboxylic acid;hydrochloride
• CAS: 856213-34-8
• 化学式: C₆H₉NO₃*ClH
• 分子量: 179.603
• InChiKey: LCVVOQSLWUTAKR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.33
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  66.4
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-oxo-3-piperidinecarboxylate hydrochloride 、 3-异丙基苯酚 在 盐酸 作用下， 以yielded the product (46.6 g) as the hydrochloride, mp 257°-261° C.的产率得到1,2,3,4-Tetrahydro-8-(1-methylethyl)-5H-[1]benzopyrano[3,4-c]pyridin-5-one hydrochloride
  参考文献：
  名称：

  3-[2-(Mono-and

  摘要：

  本发明揭示了用于治疗哺乳动物的支气管痉挛性疾病的抗胆碱能3-[2-(单烷基和双烷基氨基)-丙基]-1,2,3,4-四氢-5H-[1]苯并吡喃[3,4-c]-吡啶-5-酮。还揭示了制备所述化合物的方法，包含它们的制药组合物和使用所述制药组合物的方法。还揭示了制备本发明所需的未取代苯并吡喃-[3,4-c]吡啶-5-酮中间体的方法。

  公开号：

  US04382939A1

文献信息

• 3-(2-Mono-and dialkylamino)propyl(-1,2,3,4-tetrahydro-5H-(1) benzopyrano(3,4-c)pyridin-5-ones and derivatives thereof, a process for their production, and pharmaceutical compositions containing such compounds
  申请人：WARNER-LAMBERT COMPANY

  公开号：EP0087280A2

  公开（公告）日：1983-08-31

  Antichofinergic 3-[2-(mono- and dialkylamino)-propyl]-1,2,3,4-tetrahydro-5H-[1]benzopyrano [3,4-c]-pyridin-5-ones, useful for treating bronchospastic diseases in mammals, are disclosed. Also disclosed are processes for preparing the compounds, and pharmaceutical compositions containing them. The novel compounds have the following formula: where X is a lower alkyl radial, Y is hydrogen or a lower alkyl, and R', R2 and R3 are, separately, hydrogen atoms or substituents. A process for preparing the intermediate which is required to prepare the unsubstituted benzopyrano-[3,4-c]pyridin-5- ones of the present invention is also disclosed

  本发明公开了可用于治疗哺乳动物支气管痉挛性疾病的抗胆碱能 3-[2-(单烷基和二烷基氨基)-丙基]-1,2,3,4-四氢-5H-[1]苯并吡喃并[3,4-c]吡啶-5-酮。 还公开了制备这些化合物的工艺和含有这些化合物的药物组合物。 这些新型化合物具有下式：其中 X 是低级烷基径向，Y 是氢或低级烷基，R'、R2 和 R3 分别是氢原子或取代基。 还公开了制备本发明未取代苯并吡喃并[3,4-c]吡啶-5-酮所需的中间体的工艺
• NOVEL BENZAMIDINE DERIVATIVES AND MEDICINAL COMPOSITION THEREOF
  申请人：YAMANOUCHI PHARMACEUTICAL CO. LTD.

  公开号：EP0810215A1

  公开（公告）日：1997-12-03

  Disclosed are benzamidine derivatives of the following general formula (I), salts thereof, hydrates thereof or solvates thereof, and pharmaceutical compositions comprising the derivatives, salts thereof, hydrates thereof or solvates thereof along with pharmaceutically-acceptable carriers. The derivatives and their compositions have GPIIb/IIIa receptor antagonistic activity and are useful for the treatment and prophylaxis of vascular system disorders as medicines for ameliorating ischemic cardiac disorders, adminicula in cardiosurgery operations or in vascular surgery operations, medicines for ameliorating cerebrovascular disorders, and medicines for ameliorating peripheral artery disorders.

  本发明公开了以下通式(I)的联苯胺衍生物、其盐类、其水合物或其溶物，以及包含这些衍生物、其盐类、其水合物或其溶物以及药学上可接受的载体的药物组合物。 这些衍生物及其组合物具有 GPIIb/IIIa 受体拮抗活性，可作为改善缺血性心脏疾病的药物、心脏外科手术或血管外科手术中的用药、改善脑血管疾病的药物以及改善外周动脉疾病的药物，用于治疗和预防血管系统疾病。
• CONNOR, D. T.;UNANGST, P. C.;SCHWENDER, CH. F.;SORRENSON, R. J.;CARETHERS+, J. HETEROCYCL. CHEM., 1984, 21, N 5, 1557-1559
  作者：CONNOR, D. T.、UNANGST, P. C.、SCHWENDER, CH. F.、SORRENSON, R. J.、CARETHERS+

  DOI：——

  日期：——
• US4382939A
  申请人：——

  公开号：US4382939A

  公开（公告）日：1983-05-10
• 3-[2-(Mono-and
  申请人：Warner Lambert Company

  公开号：US04382939A1

  公开（公告）日：1983-05-10

  Anticholinergic 3-[2-(mono- and dialkylamino)-propyl]-1,2,3,4-tetrahydro-5H-[1]benzopyrano[3,4-c]-pyridin- 5-ones useful for treating bronchospastic diseases in mammals are disclosed. Also disclosed are methods for preparing said compounds, pharmaceutical compositions containing them and methods for using said pharmaceutical compositions. A method for preparing the intermediate which is required to prepare the unsubstituted benzopyrano-[3,4-c]pyridin-5-ones of the invention is also disclosed.

  翻译结果如下： 披露了用于治疗哺乳动物支气管痉挛性疾病的抗胆碱能3-[2-(单和二烷基氨基)-丙基]-1,2,3,4-四氢-5H-[1]苯并吡喃[3,4-c]吡啶-5-酮。还披露了制备所述化合物的方法、包含它们的药物组合物以及使用所述药物组合物的方法。还披露了制备本发明所需的不取代苯并吡喃[3,4-c]吡啶-5-酮的中间体的方法。